April 16, 2025
Our team developed a comprehensive suite of precision assays to support every stage of antibody-drug conjugate (ADC) development.
From confirming target expression and measuring density, to evaluating drug-target engagement, pharmacokinetics, and safety, CellCarta employs a data-driven, multiplatform approach.
Our solutions include multiplex IF and IHC, flow cytometry, mass spectrometry, RNA sequencing, and spatial biology technologies, ensuring precise target quantification and in-depth tumor microenvironment analysis.
With global facilities, companion diagnostic (CDx) expertise, and full logistics support, CellCarta helps biopharma partners accelerate their ADC programs.
Advance your ADC programs with CellCarta! Contact us today to discover how our precision assays and scientific expertise can drive your clinical success.
